101 – 110 of 186
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
(
- Contribution to journal › Article
-
Mark
Acute reduction of cerebrospinal fluid volume prior to spinal anesthesia : implications for sensory block extent
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders
(
- Contribution to journal › Article
-
Mark
CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
(
- Contribution to journal › Article
-
Mark
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease from Other Neurodegenerative Disorders
(
- Contribution to journal › Article
-
Mark
The implications of different approaches to define AT(N) in Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Relevance of biomarkers across different neurodegenerative
(
- Contribution to journal › Scientific review
-
Mark
The A4 study : β-amyloid and cognition in 4432 cognitively unimpaired adults
(
- Contribution to journal › Article